Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Jacob Wackerhausen/iStock via Getty Images Incyte Corporation (NASDAQ:INCY) has been able to achieve several key milestones over the past year, many of which, I believe, could drive shareholder growth. On one front, I believe that this company could be in a position to grow its Monjuvi drug franchise. Why is that? That's because this CD19 targeting monoclonal antibody in combination with lenalidomide was given Accelerated Approval by the FDA and Conditional Marketing Authorization by the European Medicines ...